- Home
- / SCM Lifescience
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
SCM Lifescience financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩1.9 K
2024-10-29
Market Capitalization
₩38.9 B
2024-10-29
Revenue
₩824.8 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|
| Revenue | 320.0M | 439.3M | 396.0M | 695.7M | 824.8M |
| Cost of goods sold | (7.3B) | (2.0B) | (3.8B) | (390.5M) | (274.7M) |
| Gross profit | 8.0B | 2.5B | 4.2B | 1.1B | 1.3B |
| Gross profit margin, % | 2504.8% | 572.0% | 1055.4% | 158.2% | 157.2% |
| Operating expense total | 22.5B | 13.5B | 15.7B | 13.2B | 11.5B |
| Depreciation and amortization | 1.2B | 1.1B | 1.0B | 839.4M | 924.5M |
| EBITDA | (5.3B) | (21.0B) | (23.2B) | (22.8B) | (10.3B) |
| EBITDA margin, % | -1660.4% | -4777.9% | -5855.6% | -3279.7% | -1242.9% |
| EBIT | (7.1B) | (22.5B) | (24.2B) | (23.7B) | (12.8B) |
| EBIT margin, % | -2216.1% | -5126.8% | -6121.5% | -3411.9% | -1545.9% |
| Interest income | 178.7M | 202.1M | 246.9M | 86.8M | 238.7M |
| Interest expense | 507.5M | 197.6M | 238.8M | 312.6M | 260.0M |
| Pre tax profit | (9.6B) | (22.5B) | (22.9B) | (24.0B) | (13.0B) |
| Income tax expense | (661.4M) | ||||
| Net Income | (9.6B) | (22.5B) | (22.9B) | (24.0B) | (12.4B) |